Exploratory study on continuation of COVID-19 Vaccination Programme RIVM has commissioned ABDTOPconsult to do an independent exploratory study on systematic approaches to organising and incorporating the current RIVM COVID-19 Vaccination Programme.
Early indicators added to coronavirus monitoring in sewage on Coronavirus Dashboard This week, early indicators were added to the sewage measurements page on the Coronavirus Dashboard provided by the national government. These values help to clarify the measurements by indicating how serious the situation is.
Delta variant on the rise The delta variant of the coronavirus SARS-CoV-2 is occurring more and more often in the Netherlands.
COVID-19 vaccination very effective: major drop in positive tests, hospital admissions and deaths among older people People over 75 years old living at home are 82% protected against testing positive for COVID-19 from three weeks after the second vaccination.
Launch of the European project RISK-HUNT3R The new Horizon 2020 project RISK-HUNT3R: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs was launched on 1 June.
Effects of COVID-19 vaccination becoming increasingly visible In the past calendar week, there were 43% fewer hospital admissions of patients with COVID-19 compared to the week before.
At least 87% of people over 65 vaccinated at least once: high turnout, few regional differences Four months after the launch of the vaccination campaign, at least 87% of people over 65 in the Netherlands have been vaccinated against COVID-19 at least once.
Quality assessment of SARS-CoV-2 antigen test diagnostics: good performance at public test sites in the Netherlands In their role as WHO reference laboratories, RIVM and Erasmus UMC conducted a study on the quality of SARS-CoV-2 antigen diagnostics in the Netherlands.
Long-term symptoms more common after Lyme disease More than a quarter of people with Lyme disease continue to have long-term symptoms that lead to limitations in daily life even after treatment.
RIVM updates guidelines for AstraZeneca interval As of 21 May, RIVM updated the guidelines for the interval between two doses of the AstraZeneca vaccine. The interval can now be between 6 and 14 weeks.